Pretax income is the income that a company earns before paying income taxes. Incyte's pretax income for the
three
months ended in Dec. 2023 was $271 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $834 Mil.
Incyte's pretax margin was 26.74%.
During the past 13 years, Incyte's highest Pretax Margin was 22.57%. The lowest was -20.33%. And the median was 7.92%.
Incyte Pre-Tax Income Historical Data
The historical data trend for Incyte's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Incyte's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte Pre-Tax Income Distribution
For the Biotechnology industry and Healthcare sector, Incyte's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Incyte's Pre-Tax Income falls into.
Incyte Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Incyte's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $834 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (NAS:INCY) Pre-Tax Income Explanation
Incyte's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Incyte's highest Pretax Margin was 22.57%. The lowest was -20.33%. And the median was 7.92%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Incyte's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INCY has been successfully added to your 